Journal of Diabetes Research & Clinical Metabolism

Journal of Diabetes Research & Clinical
Metabolism

ISSN 2050-0866
Commentary

Measuring and interpreting patient-reported outcome data from clinical trials of diabetes medication

Matthew Reaney* and Chad Gwaltney

*Correspondence: Matthew Reaney matthew.reaney@ert.com

Author Affiliations

eResearch Technology Inc. (ERT), Peterborough Business Park, Lynch Wood, Peterborough, PE2 6FZ, UK.

Abstract

Some treatment strategies may negatively impact psychosocial functioning while striving for good clinical and physical outcomes. Patient-reported outcome measures (PROMs) are increasingly incorporated into the clinical development of new treatment to understand the patients' perspective of treatment effects in clinical trials. However, it is sometimes difficult for researchers and healthcare professionals to review PROM data, as meaningful interpretation requires a different mindset from looking at traditional clinical endpoint data. This article provides assistance for reading and interpreting PROM endpoints. It proposes that the reader firstly looks for evidence of no detriment with the experimental therapy, then for improvement, and where study design and prior analyses support it, a comparison of change in PROM scores between the experimental and control therapies. The article provides explanation and rationale for this hierarchy of PROM interpretation.

Keyword: Patient reported outcome measures, clinical trials, diabetes, treatment

ISSN 2050-0866
Volume 3
Abstract Download